- Stocks
- Healthcare
- NASDAQ: CORT

Price (delayed)

$28.14

Market cap

$3.27B

P/E Ratio

29.62

Dividend/share

N/A

EPS

$0.95

Enterprise value

$3.24B

The company's equity rose by 46% YoY and by 8% QoQ

The quick ratio is up by 34% year-on-year and by 3.4% since the previous quarter

The P/E is 87% more than the last 4 quarters average of 15.8 but 56% less than the 5-year quarterly average of 67.7

CORT's net income is up by 26% YoY but it is down by 4.1% QoQ

What are the main financial stats of CORT

Market
Valuations
Earnings

Shares outstanding

116.17M

Market cap

$3.27B

Enterprise value

$3.24B

Price to earnings (P/E)

29.62

Price to book (P/B)

6.64

Price to sales (P/S)

9.15

EV/EBIT

24.43

EV/EBITDA

24.02

EV/Sales

9.1

Revenue

$356.03M

EBIT

$132.71M

EBITDA

$134.94M

Free cash flow

$164.41M

Per share
Balance sheet
Liquidity

EPS

$0.95

Free cash flow per share

$1.42

Book value per share

$4.24

Revenue per share

$3.08

TBVPS

$4.62

Total assets

$534.13M

Total liabilities

$44.45M

Debt

$3.03M

Equity

$489.68M

Working capital

$420.45M

Debt to equity

0.01

Current ratio

10.77

Quick ratio

10.47

Net debt/EBITDA

-0.2

Margins
Efficiency
Dividend

EBITDA margin

37.9%

Gross margin

98.4%

Net margin

30.7%

Operating margin

37.3%

Return on assets

23.2%

Return on equity

25.4%

Return on invested capital

34.5%

Return on capital employed

27%

Return on sales

37.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Corcept Therapeutics stock price performed over time

Intraday

1.88%

1 week

3.57%

1 month

7.49%

1 year

122.27%

YTD

7.57%

QTD

7.57%

How have Corcept Therapeutics's revenue and profit performed over time

Revenue

$356.03M

Gross profit

$350.27M

Operating income

$132.71M

Net income

$109.4M

Gross margin

98.4%

Net margin

30.7%

Corcept Therapeutics's operating income has increased by 31% YoY but it has decreased by 6% from the previous quarter

CORT's net income is up by 26% YoY but it is down by 4.1% QoQ

The gross profit is up by 25% year-on-year

The revenue rose by 25% year-on-year

What is Corcept Therapeutics's growth rate over time

What is Corcept Therapeutics stock price valuation

P/E

29.62

P/B

6.64

P/S

9.15

EV/EBIT

24.43

EV/EBITDA

24.02

EV/Sales

9.1

The P/E is 87% more than the last 4 quarters average of 15.8 but 56% less than the 5-year quarterly average of 67.7

The EPS has grown by 25% year-on-year but it has declined by 4% since the previous quarter

The stock's price to book (P/B) is 70% more than its last 4 quarters average of 3.9 but 45% less than its 5-year quarterly average of 12.1

The company's equity rose by 46% YoY and by 8% QoQ

CORT's P/S is 87% above its last 4 quarters average of 4.9 and 9% above its 5-year quarterly average of 8.4

The revenue rose by 25% year-on-year

How efficient is Corcept Therapeutics business performance

CORT's ROIC is down by 16% since the previous quarter and by 15% year-on-year

The return on equity has declined by 13% since the previous quarter and by 13% year-on-year

CORT's return on assets is down by 12% since the previous quarter and by 11% year-on-year

The return on sales has declined by 7% since the previous quarter but it has grown by 4.8% year-on-year

What is CORT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CORT.

How did Corcept Therapeutics financials performed over time

The company's total assets rose by 46% YoY and by 7% QoQ

The quick ratio is up by 34% year-on-year and by 3.4% since the previous quarter

Corcept Therapeutics's debt is 99% lower than its equity

The company's equity rose by 46% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.